Mainz Biomed Bv Stock Today
| MYNZ Stock | USD 0.26 0.03 13.04% |
Performance0 of 100
| Odds Of DistressOver 81
|
Mainz Biomed is trading at 0.26 as of the 27th of November 2024; that is 13.04 percent up since the beginning of the trading day. The stock's open price was 0.23. Mainz Biomed has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Mainz Biomed BV are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of May 2024 and ending today, the 27th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of November 2021 | Category Healthcare | Classification Health Care |
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic and research use only tests for clinical diagnostics in human genetics. The company was founded in 2008 and is based in Mainz, Germany. Mainz Biomed is traded on NASDAQ Exchange in the United States.. The company has 64.04 M outstanding shares of which 1.52 M shares are now shorted by private and institutional investors with about 0.76 trading days to cover. More on Mainz Biomed BV
Moving against Mainz Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Mainz Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMainz Biomed can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mainz Biomed's financial leverage. It provides some insight into what part of Mainz Biomed's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mainz Biomed BV (MYNZ) is traded on NASDAQ Exchange in USA. It is located in Robert Koch Strasse 50, Mainz, Germany, 55129 and employs 65 people. Mainz Biomed is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 14.41 M. Mainz Biomed BV conducts business under Biotechnology sector and is part of Health Care industry. The entity has 64.04 M outstanding shares of which 1.52 M shares are now shorted by private and institutional investors with about 0.76 trading days to cover.
Mainz Biomed BV currently holds about 26.01 M in cash with (21.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Mainz Biomed Probability Of Bankruptcy
Ownership AllocationMainz Biomed BV maintains a total of 64.04 Million outstanding shares. Mainz Biomed BV holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Mainz Ownership Details
Mainz Biomed Historical Income Statement
Mainz Stock Against Markets
Mainz Biomed Corporate Management
| Corinna Gorges | Head RD | Profile | |
| Chris PMP | Chief Officer | Profile | |
| Frank KriegSchneider | Chief Officer | Profile | |
| Darin Leigh | Chief Officer | Profile | |
| Philipp Freese | Chief Officer | Profile | |
| Petra Ploesser | Head Quality | Profile | |
| Guido Baechler | CEO Director | Profile |
Additional Tools for Mainz Stock Analysis
When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.